Last updated on June 2019

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years With OLE


Brief description of study

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years.

Part 1: Approximately 20 weeks (includes screening and double-blind treatment).

  • Screening will be performed based on the inclusion exclusion criteria specified in the study protocol.
  • Randomize approximately 288 subjects into the double-blind crossover phase.

Part 2: Approximately 100 subjects who complete the double-blind crossover phase will enter part 2, a 6 month open-label safety extension (OLE).

Efficacy will be evaluated in the double-blind part of the trial. Safety will be evaluated in both the double-blind and the OLE.

Clinical Study Identifier: NCT03275922

Find a site near you

Start Over

Blue Sky Neurology (106)

Englewood, CO United States
  Connect »

Precision Clinical Research, LLC. (135)

Lauderdale Lakes, FL United States
  Connect »

Axcess Medical Research (126)

Loxahatchee Groves, FL United States
  Connect »

Laszlo J. Mate, M.D., P.A. (153)

North Palm Beach, FL United States
  Connect »

East Florida Research (143)

Port Saint Lucie, FL United States
  Connect »

Mercy Research (116)

Saint Louis, MO United States
  Connect »

Granger Medical Holladay (111)

Salt Lake City, UT United States
  Connect »

Marshfield Clinic (145)

Marshfield, WI United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.